BIOGEN

HCR · Health Issues

Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials

MMM · Medicare/Medicaid

Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B progran, no specific bill.

PHA · Pharmacy

Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws.

Literal federal measure citations: H.R.1492, S.832

TAX · Taxation/Internal Revenue Code

Discussions related to H.R.1, One Big Beautiful Bill Act (2025) Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.

Literal federal measure citations: H.R.1

MAN · Manufacturing

General issues related to the manufacturing workforce

TRD · Trade (domestic/foreign)

Trade-related public policy around tariffs and intellectual property, no related bills